MDT presenta TMR1370, que permite más de dos años de funcionamiento en modo de espera en dispositivos de MCG

This is primarily a positioning event in a long qualification cycle, not an earnings event. In CGM, the value is usually captured by the device OEM through thinner form factors, longer shelf life, and fewer battery-related failure modes; the component supplier only monetizes if the design actually ships at volume. So the market should treat this as evidence of technical relevance, not as a near-term revenue step-up for MDT.

The second-order implication is broader pressure on sensor BOMs and power budgets across wearables, not just CGM. If this architecture is genuinely qualified, it lowers the barrier for smaller OEMs and Asian ODMs to offer competitive devices, which can intensify pricing pressure on incumbent CGM platforms over 6-18 months. That is mildly negative for legacy magnetic sensor vendors with higher quiescent draw and narrower package options, while the main beneficiaries are CGM brands that can market smaller and longer-lasting devices.

Near term, the catalyst is weak because medtech adoption requires validation, supply assurance, and customer integration. The thesis only becomes investable if the company converts the press release into a named design win or if management discloses meaningful production ramps; otherwise the move should fade. Falsifiers are simple: no customer adoption over the next 1-2 quarters, or a competing sensor family from larger analog/magnetic peers showing better qualification, pricing, or power performance.

Contrarian view: the consensus may be overvaluing the headline as a growth signal when it is really a defensive product-refresh story. The more important read-through is that power efficiency remains a core battleground in CGM, which could support incremental product differentiation but also compress margins as suppliers compete on ever-smaller package and power targets.